Trial · NCT04750278
Adverse events51
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 51
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | FP-025 300 mg | 8 | 30 | 8 |
| other | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | FP-025 100 mg | 7 | 28 | 10 |
| other | Respiratory, thoracic and mediastinal disorders | Respiratory, thoracic and mediastinal disorders | Placebo | 5 | 30 | 5 |
| other | Infections and infestations | Infections and infestations | FP-025 300 mg | 5 | 30 | 6 |
| other | Infections and infestations | Infections and infestations | FP-025 100 mg | 7 | 28 | 13 |
| other | Infections and infestations | Infections and infestations | Placebo | 7 | 30 | 9 |
| other | Cardiac disorders | Cardiac disorders | FP-025 300 mg | 5 | 30 | 6 |
| other | Cardiac disorders | Cardiac disorders | FP-025 100 mg | 6 | 28 | 9 |
| other | Cardiac disorders | Cardiac disorders | Placebo | 5 | 30 | 9 |
| other | Gastrointestinal disorders | Gastrointestinal disorders | FP-025 300 mg | 5 | 30 | 8 |
| other | Gastrointestinal disorders | Gastrointestinal disorders | FP-025 100 mg | 3 | 28 | 4 |
| other | Gastrointestinal disorders | Gastrointestinal disorders | Placebo | 4 | 30 | 7 |
| other | Metabolism and nutrition disorders | Metabolism and nutrition disorders | FP-025 300 mg | 3 | 30 | 4 |
| other | Metabolism and nutrition disorders | Metabolism and nutrition disorders | FP-025 100 mg | 4 | 28 | 5 |
| other | Metabolism and nutrition disorders | Metabolism and nutrition disorders | Placebo | 3 | 30 | 3 |
| other | Renal and urinary disorders | Renal and urinary disorders | FP-025 300 mg | 3 | 30 | 3 |
| other | Renal and urinary disorders | Renal and urinary disorders | FP-025 100 mg | 3 | 28 | 3 |
| other | Renal and urinary disorders | Renal and urinary disorders | Placebo | 3 | 30 | 3 |
| other | Psychiatric disorders | Psychiatric disorders | FP-025 300 mg | 2 | 30 | 2 |
| other | Psychiatric disorders | Psychiatric disorders | FP-025 100 mg | 6 | 28 | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04750278/events